-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Market data
| Aclasta | Arixtra | Diprivan | Fraxiparine | Sandostatin | Teriparatide |
|---|---|---|---|---|---|
| Bone calcium regulators | Antithrombotic agent | General anaesthetic | Low molecular weight heparin | Hormone replacement – bone and tumour regimens | Parathyroid hormone analog |
0
Products
Launched
Launched
(2024: 17)
0
Product
Recalls
Recalls
(2024: Nil)
0
%
Average Staff
Turnover
Turnover
(2024: 28%)
0
Work-related
Fatalities
Fatalities
(2024: Nil)
100
Sales
Representatives
Representatives
(2024: 317)
1000
Permanent
Employees
Employees
June 2025
0
Permanent
Employees
Employees
June 2024
0
Products
Launched
Launched
(2022: 3)
Product
Recalls
Recalls
(2022: Nil)
10
%
Average Staff
Turnover
Turnover
(2022: 29%)
Work-related
Facilities
Facilities
(2022: Nil)
410
Sales
Representatives
Representatives
(2022: 535)
900
Permanent
Employees
Employees
(June 2022: 1,166)
| Revenue | 2025 R'million |
2024 (CER) R'million |
Change % |
|---|---|---|---|
| Commercial Pharmaceuticals | 4 534 | 3 991 | 14 |
| Injectables | 3 324 | 3 029 | 10 |
| Prescription | 1 210 | 680 | 78 |
| Over the counter | 316 | 282 | 12 |
| Manufacturing | |||
| Finished dose form | 110 | 97 | 13 |
| Total | 4 960 | 4 088 | 21 |
Note: Commercial Pharmaceuticals' revenue is by customer geography and Manufacturing revenue is by place of manufacture.
CER: Constant Exchange Rate
CER: Constant Exchange Rate
Contribution to Group revenue (%)
2025
Rest of Group
89
Asia
11
Revenue by segment (%)
2025
Injectables
67
Prescription
25
Over the counter
6
Finished dose form
2
- The market value of Somatostatin and its analogs in June 2025 was EUR152,8 million, compared to EUR186,3 million in the prior year. The decline in market value is due to the Somatostatin volume-based procurement and the price reduction of Octreotide. Aspen’s Sandostatin held 21,0% market share as at June 2025, a growth of 2,6% compared to June 2024*.
- The market value of Zoledronic in June 2025 was EUR36,8 million, with a 6,5% decrease of total market compared to the prior year due to national volume-based procurement and competition from Denosumba*.
- Aspen’s Aclasta held 5,3% as at June 2025, a decrease of 3,8% compared to June 2024*.
Source: China IMS CHPA Report, June 2025.
